fiercepharma.com

Daiichi Sankyo Wins ¥203B Suit as Samsung Bio Signs $262M Deal

Daiichi Sankyō logoDaiichi Sankyō
Sig4.70Sen+4.10Env0.00Soc+0.20Gov+1.60
Samsung Biologics logoSamsung Biologics
Sig3.25Sen+3.00Env0.00Soc0.00Gov0.00
Takeda Pharmaceutical logoTakeda Pharmaceutical
Sig1.55Sen+2.25Env0.00Soc0.00Gov0.00

Samsung Biologics signed a $262 million contract with production planned on its Songdo, South Korea campus through end-2033. Takeda’s long-serving R&D chief Andy Plump will retire in June 2027 after pipeline wins. A Tokyo court dismissed a Northern TK Venture damages lawsuit seeking 203 billion yen, tied to a legacy Ranbaxy dispute that supported Daiichi Sankyo’s position. Solstice raised $225 million to move a CTLA-4 antibody into phase 2.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro